Recently, SaiPu Biotech, a leading high-end biomedical innovation enterprise in China, announced the completion of a Series B financing round worth several hundred million RMB. This round was jointly invested by YuanSheng Venture Capital and CICC Qichen Fund (under CICC Capital), with follow-on investments from Xiamen Venture Capital and China-Singapore Group. Existing shareholders — Sunshine Ronghui Capital, Orient Jiafu Capital, Jiale Capital, YuanHe Houwang, YuanHe Holdings, and Shunrong Capital — continued their support. The funds raised will be used to further strengthen the R&D and production of high-end biomedical consumables, accelerate the development of biopharmaceutical consumables, and expand international market presence, advancing the company to higher levels, broader scope, and deeper domains.

SaiPu Biotech is a company specializing in the R&D, production, and sales of high-end biomedical consumables. It is committed to providing global customers with high-quality consumables and customized services in areas such as molecular diagnostics, cell culture, and immunotherapy.

Beijing Caihe Law Firm conducted the Freedom-to-Operate (FTO) due diligence for patent infringement risks in this financing round.